1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN,
Masana L, Descamps OS, et al. Familial hypercholesterolaemia
is underdiagnosed and undertreated in the general population:
Guidance for clinicians to prevent coronary heart disease. Eur
Heart J 2013; 34: 3478 – 3490.
2. Harada-Shiba M, Arai H, Ishigaki Y, Okamura T, Ogura M,
Dobashi K, et al. Guidelines for diagnosis and treatment of
familial hypercholesterolemia 2017. J Atheroscler Thromb 2018;
25: 751 – 770.
3. Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of
coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225 – 332.
4. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et
al. Familial hypercholesterolemia: Executive summary of the
Japan Atherosclerosis Society guidelines for the diagnosis and
prevention of atherosclerotic cardiovascular diseases in Japan –
2012 version. J Atheroscler Thromb 2014; 21: 6 – 10.
5. Gencer B, Nanchen D. Identifying familial hypercholesterolemia
in acute coronary syndrome. Curr Opin Lipidol 2016; 27:
375 – 381.
6. Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, et al. An
enquiry based on a standardised questionnaire into knowledge,
awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the AsiaPacific region: The “ten Countries Study.” BMJ Open 2017; 7:
1 – 9.
7. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky
AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:
1544 – 1568.
8. Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu
A, et al. Estimating the prevalence of heterozygous familial
hypercholesterolaemia: A systematic review and meta-analysis.
BMJ Open 2017; 7: 1 – 13.
9. Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri
MA, Tada H, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of
Japan. Atherosclerosis 2011; 214: 404 – 407.
10. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG.
Familial hypercholesterolemia in the Danish general population:
Prevalence, coronary artery disease, and cholesterol-lowering
medication. J Clin Endocrinol Metab 2012; 97: 3956 – 3964.
11. Sjouke B, Kusters DM, Kindt I, Besseing J, Defesche JC, Sijbrands
EJG, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: Prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36: 560 – 565.
12. Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37: 402 – 407.
13. Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S,
Matsuzawa Y, et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996 – 1998 by the research
committee of the Ministry of Health, Labour and Welfare of
Japan. J Atheroscler Thromb 2004; 11: 146 – 151.
14. Maruyama T, Miyake Y, Tajima S, Harada-Shiba M, Yamamura
T, Tsushima M, et al. Common mutations in the low-densitylipoprotein–receptor gene causing familial hypercholesterolemia
in the Japanese population. Arterioscler Thromb Vasc Biol 1995;
15: 1713 – 1718.
15. Harada-Shiba M, Ako J, Arai H, Hirayama A, Murakami Y,
Nohara A, et al. Prevalence of familial hypercholesterolemia in
patients with acute coronary syndrome in Japan: Results of the
EXPLORE-J study. Atherosclerosis 2018; 277: 362 – 368.
Advance Publication
10
16. Ohmura H, Fukushima Y, Mizuno A, Niwa K, Kobayashi Y,
Ebina T, et al. Estimated prevalence of heterozygous familial
hypercholesterolemia in patients with acute coronary syndrome:
Multicenter registration study in Japan. Int Heart J 2017; 58:
88 – 94.
17. Nanchen D, Gencer B, Muller O, Auer R, Aghlmandi S, Heg D,
et al. Prognosis of patients with familial hypercholesterolemia
after acute coronary syndromes. Circulation 2016; 134: 698 – 709.
18. Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL,
Bittner VA, et al. Alirocumab in patients with polyvascular disease
and recent acute coronary syndrome: ODYSSEY OUTCOMES
Trial. J Am Coll Cardiol 2019; 74: 1167 – 1176.
19. Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW,
de Groot E, et al. 20-Year follow-up of statins in children with
familial hypercholesterolemia. N Engl J Med 2019; 381:
1547 – 1556.
20. Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby
AJ, et al. Effect of alirocumab on mortality after acute coronary
syndromes: An analysis of the ODYSSEY OUTCOMES
Randomized Clinical Trial. Circulation 2019; 140: 103 – 112.
21. Masuda J, Kishi M, Kumagai N, Yamazaki T, Sakata K,
Higuma T, et al. Rural-urban disparity in emergency care for
acute myocardial infarction in Japan. Circ J 2018; 82:
1666 – 1674.
22. Fukuoka S, Kurita T, Dohi K, Masuda J, Seko T, Tanigawa T,
et al. Untangling the obesity paradox in patients with acute
myocardial infarction after primary percutaneous coronary
intervention. Int J Cardiol 2019; 289: 12 – 18.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem 1972;
18: 499 – 502.
24. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR,
White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581 – 1598.
25. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi
S, et al. Japan Atherosclerosis Society guidelines for prevention
of atherosclerotic cardiovascular diseases 2017. J Atheroscler
Thromb 2018; 25: 846 – 984.
26. Mabuchi H, Ito S, Haba T, Ueda K, Ueda R, Tatami R, et al.
TAKASAKI A et al.
Discrimination of familial hypercholesterolemia and secondary
hypercholesterolemia by achilles’ tendon thickness. Atherosclerosis 1977; 28: 61 – 67.
27. Rosenson RS. Myocardial injury: The acute phase response and
lipoprotein metabolism. J Am Coll Cardiol 1993; 22: 933 – 940.
28. Ryder RE, Hayes TM, Mulligan IP, Kingswood JC, Williams S,
Owens DR. How soon after myocardial infarction should plasma
lipid values be assessed? BMJ 1984; 289: 1651 – 1653.
29. Henkin Y, Crystal E, Goldberg Y, Friger M, Lorber J, Zuili I, et
al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J
Cardiol 2002; 89: 7 – 11.
30. Wattanasuwan N, Khan IA, Gowda RM, Vasavada BC, Sacchi
TJ. Effect of acute myocardial infarction on cholesterol ratios.
Chest 2001; 120: 1196 – 1199.
31. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK,
Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/
ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the
Management of Blood Cholesterol: A report of the American
College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines. Circulation 2019; 139:
1082 – 1143.
32. Schwartz GG. Effects of atorvastatin on early recurrent ischemic
events in acute coronary syndromes. The MIRACL Study: A
randomized controlled trial. JAMA 2001; 285: 1711 – 1718.
33. Lee KH, Jeong MH, Kim HM, Ahn Y, Kim JH, Chae SC, et al.
Benefit of early statin therapy in patients with acute myocardial
infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol 2011; 58: 1664 – 1671.
34. Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D,
et al. Familial hypercholesterolemia among young adults with
myocardial infarction. J Am Coll Cardiol 2019; 73: 2439 – 2450.
35. Nakamura M, Ako J, Arai H, Hirayama A, Murakami Y,
Nohara A, et al. Investigation into lipid management in acute
coronary syndrome patients from the EXPLORE-J study. J
Atheroscler Thromb 2019; 26: 559 – 572.
Supplementary Files
Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-20-0112
...
論文の公開元へ
